To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
118th Congress
Introduced Jan 30, 2023
Sponsors
Legislative Progress
Introduced
Introduced
Committee
Passed
Jan 30, 2023
Ms. Klobuchar (for herself, Mr. Grassley, Mr. Durbin, Mr. Cramer, …
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology